IDH1 and central nervous system cancer: Previous preclinical studies have attempted to investigate the overexpression of the IDH1 mutation in vivo [24–27] although none with the original objective of specifically investigating its pathophysiological expression by introducing the mutation in the well characterized U87 human high-grade gliomas (HGG) cell lines using CRISPR/Cas9.